Ci Investments Inc. Zymeworks Inc. Transaction History

Ci Investments Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$4.65 - $7.43 $919,212 - $1.47 Million	-197,680 Reduced 57.44%	146,470 $901,000
Q2 2022 Aug 12, 2022	BUY	$4.82 - $7.7 $892,182 - $1.43 Million	185,100 Added 116.38%	344,150 $1.82 Million
Q1 2022 May 12, 2022	BUY	$6.0 - $16.98 $469,452 - $1.33 Million	78,242 Added 96.82%	159,050 $1.04 Million
Q4 2021 Feb 11, 2022	BUY	$15.19 - $29.33 $685,069 - $1.32 Million	45,100 Added 126.3%	80,808 $1.32 Million
Q3 2021 Nov 12, 2021	SELL	$27.35 - $37.28 $385,115 - $524,939	-14,081 Reduced 28.28%	35,708 $1.04 Million
Q2 2021 Aug 13, 2021	SELL	$26.5 - $38.23 $336,550 - $485,520	-12,700 Reduced 20.32%	49,789 $1.73 Million
Q1 2021 May 13, 2021	BUY	$29.83 - $56.81 $1.05 Million - $2 Million	35,289 Added 129.74%	62,489 $1.97 Million
Q4 2020 Feb 09, 2021	BUY	$39.12 - $54.99 $70,416 - $98,982	1,800 Added 7.09%	27,200 $1.29 Million
Q3 2020 Nov 09, 2020	BUY	$29.21 - $46.58 $613,410 - $978,180	21,000 Added 477.27%	25,400 $1.18 Million
Q2 2020 Aug 07, 2020	BUY	$33.67 - $40.0 $3,367 - $4,000	100 Added 2.33%	4,400 $159,000
Q1 2020 Aug 07, 2020	BUY	$24.28 - $49.8 $104,404 - $214,140	4,300 New	4,300 $153,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $872M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Ci Investments Inc., based on Form 13F filings with the SEC.

Stay updated on Ci Investments Inc. with notifications on news.